Droxidopa

SKU: orb1305333

Description

Droxidopa is an orally active, blood-brain barrier permeable precursor to norepinephrine. It is utilized in research for neurogenic orthostatic hypotension (nOH) and as an alternative ADHD treatment model, with studies demonstrating its ability to elevate blood pressure and improve orthostatic tolerance in vivo.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 23651-95-8
• MW: 213.19
• Purity: 99.88% (May vary between batches)
• Formula: C₉H₁₁NO₅
• SMILES: N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O
• Target: Adrenergic Receptor
• Solubility: H2O:1.25 mM;DMSO:2.14 mg/mL (10.04 mM)

Bioactivity

• In Vivo:
  Droxidopa is administered orally and is absorbed and converted to norepinephrine by the enzyme dopa decarboxylase, which, together with endogenous norepinephrine, increases neurotransmitter levels.Droxidopa also crosses the blood-brain barrier (BBB) and is converted to norepinephrine and epinephrine in the brain.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Inhibitor, orally active, neurogenic orthostatic hypotension, L-DOPS, AdrenergicReceptor, ADHD, Adrenergic Receptor, blood pressure, Beta Receptor, Droxidopa, DOPS, SM5688, SM-5688, SM 5688

Compound Identifiers

PubChem CID

92974